- AbbVie has started a $70 million expansion at its Bioresearch Center (ABC) in Worcester, Massachusetts, to increase biologics manufacturing capacity.
- The project will include new laboratory, warehouse, and office space and support the transfer of select oncology products from Europe to the U.S.
AbbVie announced the start of construction for a $70 million expansion at its AbbVie Bioresearch Center (ABC) in Worcester, Massachusetts. The site, a centre of excellence for biologics research, development, and manufacturing, will gain additional biologics manufacturing areas and a three-story building with laboratory, warehouse, and office facilities.
The expansion is part of AbbVie’s broader U.S. commitment to invest over $10 billion to support innovation and expand critical biologics manufacturing capabilities. It is intended to meet rising global demand for current and next-generation oncology and immunology medicines.
“This investment will further expand AbbVie’s biologics manufacturing capacity and position ABC to build upon its impressive track record of developing, manufacturing and launching next-generation complex biologic medicines that improve the lives of millions of patients worldwide.”
Azita Saleki-Gerhardt, Ph.D., executive vice president and chief operations officer at AbbVie
The project is expected to create new jobs at the Worcester site and strengthen AbbVie’s U.S. manufacturing footprint, which currently supports over 6,000 American jobs across 11 manufacturing sites. With a presence in all 50 states and Puerto Rico, AbbVie employs 28,000 people in the U.S., including more than 2,000 in Massachusetts.
